Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Neuroinflammation: A Distal Consequence of Periodontitis.

Authors:
X Li M Kiprowska T Kansara P Kansara P Li

J Dent Res 2022 Jun 16:220345221102084. Epub 2022 Jun 16.

Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY, USA.

Periodontitis, a chronic, inflammatory disease, induces systemic inflammation and contributes to the development of neurodegenerative diseases. The precise etiology of the most common neurodegenerative disorders, such as sporadic Alzheimer's, Parkinson's diseases and multiple sclerosis (AD, PD, and MS, respectively), remains to be revealed. Chronic neuroinflammation is a well-recognized component of these disorders, and evidence suggests that systemic inflammation is a possible stimulus for neuroinflammation development. Systemic inflammation can lead to deleterious consequences on the brain if the inflammation is sufficiently severe or if the brain shows vulnerabilities due to genetic predisposition, aging, or neurodegenerative diseases. It has been proposed that periodontal disease can initiate or contribute to the AD pathogenesis through multiple pathways, including key periodontal pathogens. Dysbiotic oral bacteria can release bacterial products into the bloodstream and eventually cross the brain-blood barrier; these bacteria can also cause alterations to gut microbiota that enhance inflammation and potentially affect brain function via the gut-brain axis. The trigeminal nerve has been suggested as another route for connecting oral bacterial products to the brain. PD and MS are often preceded by gastrointestinal symptoms or aberrant gut microbiome composition, and alterations in the enteric nervous system accompany the disease. Clinical evidence has suggested that patients with periodontitis are at a higher risk of developing PD and MS. This nexus among the brain, periodontal disease, and systemic inflammation heralds new ways in which microglial cells, the main innate immune cells, and astrocytes, the crucial regulators of innate and adaptive immune responses in the brain, contribute to brain pathology. Currently, the lack of understanding of the pathogenesis of neurodegeneration is hindering treatment development. However, we may prevent this pathogenesis by tackling one of its possible contributors (periodontitis) for systemic inflammation through simple preventive oral hygiene measures.

Download full-text PDF

Source
http://dx.doi.org/10.1177/00220345221102084DOI Listing
June 2022

Publication Analysis

Top Keywords

systemic inflammation
20
neurodegenerative diseases
8
bacterial products
8
periodontal disease
8
brain
7
inflammation
7
systemic
5
trigeminal nerve
4
nerve suggested
4
suggested route
4
route connecting
4
connecting oral
4
oral bacterial
4
products brain
4
brain preceded
4
preceded gastrointestinal
4
gut-brain axis
4
gastrointestinal symptoms
4
symptoms aberrant
4
aberrant gut
4

Keyword Occurance

Similar Publications

Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.

Authors:
Yumeko Kawano Naomi J Patel Xiaosong Wang Claire E Cook Kathleen Mm Vanni Emily N Kowalski Emily P Banasiak Grace Qian Michael DiIorio Tiffany Y-T Hsu Michael E Weinblatt Derrick J Todd Zachary S Wallace Jeffrey A Sparks

Ann Rheum Dis 2022 Aug 9. Epub 2022 Aug 9.

Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA

Objectives: To investigate temporal trends in incidence and severity of COVID-19 among patients with systemic autoimmune rheumatic diseases (SARDs) from the first wave through the initial Omicron wave.

Methods: We conducted a retrospective cohort study investigating COVID-19 outcomes among patientswith SARD systematically identified to have confirmed COVID-19 from 1 March 2020 to 31 January 2022 at Mass General Brigham. We tabulated COVID-19 counts of total and severe cases (hospitalisations or deaths) and compared the proportion with severe COVID-19 by calendar period and by vaccination status. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Authors:
Manuel Francisco Ugarte-Gil John Hanly Murray Urowitz Caroline Gordon Sang-Cheol Bae Juanita Romero-Diaz Jorge Sanchez-Guerrero Sasha Bernatsky Ann Elaine Clarke Daniel J Wallace David Alan Isenberg Anisur Rahman Joan T Merrill Paul R Fortin Dafna D Gladman Ian N Bruce Michelle Petri Ellen M Ginzler Mary Anne Dooley Rosalind Ramsey-Goldman Susan Manzi Andreas Jönsen Ronald F van Vollenhoven Cynthia Aranow Meggan Mackay Guillermo Ruiz-Irastorza Sam Lim Murat Inanc Ken Kalunian Søren Jacobsen

Ann Rheum Dis 2022 Aug 9. Epub 2022 Aug 9.

Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.

Objective: To determine the independent impact of different definitions of remission and low disease activity (LDA) on damage accrual.

Methods: Patients with ≥2 annual assessments from a longitudinal multinational inception lupus cohort were studied. Five mutually exclusive disease activity states were defined: remission off-treatment: clinical Systemic Lupus Erythematosus Disease Activity Index (cSLEDAI)-2K=0, without prednisone or immunosuppressants; remission on-treatment: cSLEDAI-2K score=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; low disease activity Toronto cohort (LDA-TC): cSLEDAI-2K score of ≤2, without prednisone or immunosuppressants; modified lupus low disease activity (mLLDAS): Systemic Lupus Erythematosus Disease Activity Index-2K score of 4 with no activity in major organ/systems, no new disease activity, prednisone ≤7. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

A MDM2 inhibitor MX69 inhibits adipocytes adipogenesis and differentiation.

Authors:
Wei Zhao Jiahui Yang Xianghong Xie Chunmei Li Weihong Zhang Enhui Chen Yanfang Guo Li Yan Fude Fang Hong Yao Xiaojun Liu

Biochem Biophys Res Commun 2022 Aug 2;625:9-15. Epub 2022 Aug 2.

State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences & School of Basic Medicine Peking Union Medical College, Beijing, 100005, China. Electronic address:

Adipose tissue, a key regulator of systemic energy homeostasis, can synthesize and store triglycerides to meet long-term energy demands. In response to nutrient overload, adipose tissue expands by hypertrophy or hyperplasia. As an oncogene, MDM2 has exerted diverse biological activities including human development, tissue regeneration, and inflammation, in addition to major oncogenic activities. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Signaling through free fatty acid receptor 4 attenuates cardiometabolic disease.

Authors:
Timothy D O'Connell Katherine A Murphy Naixin Zhang Sara Puccini Chastity L Healy Brian A Harsch Michael J Zhang Gregory C Shearer

Physiology (Bethesda) 2022 Aug 9. Epub 2022 Aug 9.

Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, United States.

A surge in the prevalence of obesity and metabolic syndrome, which promote systemic inflammation, underlie an increase in cardiometabolic disease. Free fatty acid receptor 4 is a nutrient sensor for long-chain fatty acids, like ω3-polyunsaturated fatty acids (ω3-PUFAs), that attenuates metabolic disease and resolves inflammation. Clinical trials indicate ω3-PUFAs are cardioprotective, and this review discusses the mechanistic links between ω3-PUFAs, Ffar4, and attenuation of cardiometabolic disease. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

[Delta-He a new biomarker for a surgical clinic].

Authors:
N B Teryaeva O A Gadzhieva V V Nazarov B A Bashiryan A B Kadasheva V A Cherekaev

Zh Vopr Neirokhir Im N N Burdenko 2022 ;86(4):60-65

Burdenko Neurosurgical Center, Moscow, Russia.

Background: Delta-He the difference between hemoglobin content in reticulocytes and erytrocytes is a relatively new laboratory indicator that is easily measured in everyday practice. This parameter is directly related to iron bioavailability for hemoglobin synthesis and can reflect various conditions accompanied by cytokine expression including systemic inflammation.

Objective: To analyze the prospects for practical application of hemoglobin delta in assessment of neurosurgical patients throughout in-hospital treatment. Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap